🧠 Stay sharp with the latest in #irAE research! From duplilumab in cutaneous toxicities to survival outcomes with inpatient ICI use—check out our curated #ASPIRE reading list 🔥. Start reading now in our latest newsletter: mailchi.mp/325da8534919/f… #Immunotherapy #irAE #MedEd

July 1st marks exciting new beginnings in medicine! To new trainees: even on the toughest days, treat others as you’d want yourself or your loved ones cared for—you’ll never go wrong. Wishing you all the best! #MedEd #OncMedEd 🎉

We are deeply saddened by the recent loss of Dr. Elopre, she was a beloved physician and advocate at UAB. Please consider supporting this GoFundMe to help secure her children's educational future. 🔗gofund.me/c322f43f

Sunvozertinib (oral EGFR inhibitor, 200mg Qd) now U.S. FDA approved based off PhII WU-KONG1 in previously treated Exon20ins mNSCLC: - Confirmed 44.9% ORR w/ 9mos DoR: 57% - ≥Gr 3: Diarrhea (17%), CPK levels (11%), and anemia (3.6%) #OncTwitter #MedTwitter

🫁 Subclonal immune evasion in NSCLC: Using organoid–T cell co-cultures from TRACERx, researchers show genetically distinct tumor subclones can evade immunity differently, even within the same tumor. Immune escape isn’t uniform, it’s evolutionary and clonal. 📖 Cancer Cell 👉

I’m coming home again! I was honored to be selected in the inaugural class of HEALing Fellows by then Vice Chancellor Dr James Keeton in 2011 as a resident physician The University of Mississippi Medical Center . Meharry Medical College had trained me well to ALWAYS be a voice for the voiceless and to advocate for

Huge kudos to our interns at UF for completing their first block on the inpatient oncology service which is a tough place to start, but they showed incredible compassion, excellence and resilience. Wishing them all the best as they continue their journey! 💪 #MedTwitter #OncMedEd

Excited to have submitted my Heme/Onc 🩸fellowship application! Would not have been possible without my mentors, and my Fiancé (future 🫁) Nikita Gupta! AAMC ID: 15136839 Especially grateful for the support from Nishant Rajendra Tiwari Loyola Heme/Onc Loyola - MacNeal Internal Medicine Residency! Looking forward to what

It feels truly surreal to be entering this hematology-oncology fellowship application cycle, pursuing my passion for GIOncology. My interests focus on GI cancers, early-onset malignancies, and healthcare disparities, with a special focus on clinical trials. Grateful to all my

Thank you to ASCO for the FASCO designation! I appreciate the opportunities to contribute over the years through collaboration, advocacy, and volunteer work. 🎉Congratulations to the other designees as well! 🎉 #Lcsm #WomeninMedicine Hematology & Oncology Women Physicians Group—HOWPG

What a terrific list of folks including so many members of the GU family - Walter Stadler City of Hope, Umang Swami Huntsman Cancer Institute, Tian Zhang, MD, MHS UTSW Simmons Cancer Center, Andrea Apolo, M.D. National Cancer Institute & so many other friends! Yelena Y. Janjigian MD Devika Das, MD, MSHQS, FASCO Erika Hamilton, MD

So glad we got to work together and looking forward to many more collaborations soon! 💖Hematology & Oncology Women Physicians Group—HOWPG and UF is lucky to have you taking charge to advance the mission of #lcsm care in Florida!

Ever been confused by your insurance company's prior authorization process? You're not alone. We asked Ashley Love Sumrall, MD, FACP, FASCO to explain what patients and caregivers should know about prior authorization: brnw.ch/21wUjvi

Treatment outcome of NSCLC patients with BRAFnon-V600Emutations: a retrospective, multicentre analysis within the nNGM Lung Cancer in Germany in ESMO Open. Different results with targeted therapies by mutation type even among non-V600E NSCLC. esmoopen.com/article/S2059-…

Physicians, researchers and clinical staff from the Cancer Center and Research Institute made a big impact at the recent Gulf Coast Hematology & Oncology Summit. We’re proud of our team for leading the way in cancer research and care across the Gulf Coast! Rod Rocconi

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. NEJM 2025 Tarlatamab, a DLL3-targeted BiTE, showed mOS of 14.3 mo in SCLC post 1L chemo +/- ICI, offering benefit in this aggressive, hard to treat setting www-nejm-org.wdg.biblio.udg.mx:8443/doi/full/10.10…

Several TKIs can inhibit OCT2 and MATE1, leading to elevated serum creatinine levels without affecting the GFR, a phenomenon known as pseudo-acute kidney injury. Sharing our correspondence regarding the same Journal of Clinical Oncology #oncmeded #lcsm ascopubs.org/doi/10.1200/JC…

Yes! That’s what we have been doing but realized that there is very awareness on this topic within the oncology community! Both in SOC and clinical trials #oncmeded Hem-Onc Fellows Network #lcsm

Thanks chadi nabhan MD, MBA, FACP for this wonderful opportunity. Hope this is helpful for our incoming and Senior fellows. IMG Oncologists Noha N. Soror, MD, MSc. 𓂀 Nazli Dizman Thor Halfdanarson The Fellow On Call ASCO ASCO PallOnc Community of Practice ASCO OncMedEdCoP Mayo Clinic Hematology-Oncology Fellowship Mayo Clinic Comprehensive Cancer Center Mayo Clinic Mayo Clinic Radiation Oncology Mayo Clinic Med Ed

Been seeing it in my practice quite often. Excellent review! #lcsm #oncMedEd